Literature DB >> 24101121

Haematological cancer: a step before the next leap?

Ravi Vij1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24101121     DOI： 10.1038/nrclinonc.2013.181

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  7 in total

1.  Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Authors:  Jesus San Miguel; Katja Weisel; Philippe Moreau; Martha Lacy; Kevin Song; Michel Delforge; Lionel Karlin; Hartmut Goldschmidt; Anne Banos; Albert Oriol; Adrian Alegre; Christine Chen; Michele Cavo; Laurent Garderet; Valentina Ivanova; Joaquin Martinez-Lopez; Andrew Belch; Antonio Palumbo; Stephen Schey; Pieter Sonneveld; Xin Yu; Lars Sternas; Christian Jacques; Mohamed Zaki; Meletios Dimopoulos
Journal:  Lancet Oncol       Date:  2013-09-03       Impact factor: 41.316

2.  Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Authors:  S K Kumar; J H Lee; J J Lahuerta; G Morgan; P G Richardson; J Crowley; J Haessler; J Feather; A Hoering; P Moreau; X LeLeu; C Hulin; S K Klein; P Sonneveld; D Siegel; J Bladé; H Goldschmidt; S Jagannath; J S Miguel; R Orlowski; A Palumbo; O Sezer; S V Rajkumar; B G M Durie
Journal:  Leukemia       Date:  2011-07-29       Impact factor: 11.528

3.  Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

Authors:  Sagar Lonial; Ravi Vij; Jean-Luc Harousseau; Thierry Facon; Philippe Moreau; Amitabha Mazumder; Jonathan L Kaufman; Xavier Leleu; L Claire Tsao; Christopher Westland; Anil K Singhal; Sundar Jagannath
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

4.  Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.

Authors:  Paul G Richardson; David Siegel; Rachid Baz; Susan L Kelley; Nikhil C Munshi; Jacob Laubach; Daniel Sullivan; Melissa Alsina; Robert Schlossman; Irene M Ghobrial; Deborah Doss; Nora Loughney; Laura McBride; Elizabeth Bilotti; Palka Anand; Lisa Nardelli; Sandra Wear; Gail Larkins; Min Chen; Mohamad H Zaki; Christian Jacques; Kenneth C Anderson
Journal:  Blood       Date:  2012-12-14       Impact factor: 22.113

5.  Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.

Authors:  S A Schey; P Fields; J B Bartlett; I A Clarke; G Ashan; R D Knight; M Streetly; A G Dalgleish
Journal:  J Clin Oncol       Date:  2004-07-12       Impact factor: 44.544

6.  Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

Authors:  Xavier Leleu; Michel Attal; Bertrand Arnulf; Philippe Moreau; Catherine Traulle; Gerald Marit; Claire Mathiot; Marie Odile Petillon; Margaret Macro; Murielle Roussel; Brigitte Pegourie; Brigitte Kolb; Anne Marie Stoppa; Bernadette Hennache; Sabine Bréchignac; Nathalie Meuleman; Beatrice Thielemans; Laurent Garderet; Bruno Royer; Cyrille Hulin; Lotfi Benboubker; Olivier Decaux; Martine Escoffre-Barbe; Mauricette Michallet; Denis Caillot; Jean Paul Fermand; Hervé Avet-Loiseau; Thierry Facon
Journal:  Blood       Date:  2013-01-14       Impact factor: 22.113

7.  Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.

Authors:  Martha Q Lacy; Suzanne R Hayman; Morie A Gertz; Angela Dispenzieri; Francis Buadi; Shaji Kumar; Philip R Greipp; John A Lust; Stephen J Russell; David Dingli; Robert A Kyle; Rafael Fonseca; P Leif Bergsagel; Vivek Roy; Joseph R Mikhael; A Keith Stewart; Kristina Laumann; Jacob B Allred; Sumithra J Mandrekar; S Vincent Rajkumar
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.